Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
U.S. FDA grants orphan drug designation for using rigosertib in MDS and pancreatic cancer.

SymBio Pharmaceuticals Limited has announced that clinical trial notification (CTN) has been accepted for its Phase 1 clinical trial using rigosertib (SyB L-1101) in refractory and relapsed myelodysplastic syndrome (MDS) patients.

Onconova Therapeutics, Inc., a U.S.-based biopharmaceutical company which has licensed rigosertib to SymBio, is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India in hematological cancers and solid tumors.

A pivotal Phase III trial in refractory/relapsed MDS patients was initiated under a Special Protocol Assessment from the U.S. FDA and is underway at more than 50 centers in the U.S. and Europe.

The U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS and pancreatic cancer.

In addition to the intravenous product in advanced-stage development and with the successful completion of two Phase I trials, an oral formulation of rigosertib is being developed for frontline MDS in Phase II trials and other indications.

To date, more than 500 cancer patients have been treated with rigosertib in Phase I, II and III clinical trials conducted in the U.S., EU and India.

As well as this first trial for the treatment of refractory and relapsed MDS patients, SymBio is planning to initiate a Phase I clinical trial for the treatment of frontline MDS using the oral form of rigosertib (SyB C-1101) based on promising results generated in U.S. Phase II clinical trials.

Patients with MDS often require frequent blood transfusions due to the development of severe anemia (decrease in number of red blood cells), with approximately one third of patients progressing to acute myelogenous leukemia (AML).

MDS remains an underserved therapeutic area with few available treatment options for patients, hence SymBio is moving rigosertib through clinical development as nimbly as possible.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SymBio Initiates Japanese Phase I Trial of Oral Rigosertib (SyB C-1101) in Frontline MDS
U.S. FDA has granted orphan drug designation for the use of rigosertib in MDS.
Thursday, July 25, 2013
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!